EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Integration of Chromogenic RNAscope In Situ Hybridization for Target Validation in Drug Discovery

Rosanna Win, Wesley Minto, In Kyoung Mah, Kelli Boyd iD

Toxicologic Pathology · 2025-01 · 53 (1) · 21-30

DOI: 10.1177/01926233241311275 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxicologic Pathology, online erschienen am 19.01.2025. Verfasst von Rosanna Win und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Foster City, California, USA. Hauptthemen laut MEDLINE: In Situ Hybridization, Drug Discovery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Characterizing the expression of novel targets in normal and diseased tissues is a fundamental component of a target validation data package. Often these targets are presented to the pathology team for assessment with bulk or single-cell RNAseq data and limited to no spatial tissue expression data. In situ hybridization to detect mRNA (RNAscope) is a valuable tool to (1) identify cells that may express the target protein and to corroborate protein expression during immunohistochemical (IHC) assay development or (2) to use as surrogate for single-cell expression IHC when antibodies are not available. Chromogenic RNAscope in situ hybridization (CISH) can be performed on frozen or formalin-fixed, paraffin-embedded (FFPE) tissues. This CISH workflow starts with RNA qualification of the tissue (to assess RNA integrity) by measuring the expression of housekeeping genes. RNA-qualified tissues then undergo CISH for the target in question, and positive CISH signals are quantified in VisioPharm by a combination of color deconvolution, size gating, and dot density thresholding. This RNA workflow can complement IHC or standalone in target validation for spatial characterization of novel targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

In Situ HybridizationDrug DiscoveryHumansRNA, MessengerChromogenic CompoundsImmunohistochemistry

Stichwörter der Autor:innen

RNAscopeimmunohistochemistryin situ hybridizationquantitative image analysistarget validation

Substanzen

RNA, MessengerChromogenic Compounds

Autor:innen und Institutionen

  • Gilead Sciences, Foster City, California, USA.

ORCID-Profile: Kelli Boyd

Zitieren

APA

Win, R., Minto, W., Mah, I. K., & Boyd, K. (2025). Integration of Chromogenic RNAscope In Situ Hybridization for Target Validation in Drug Discovery. Toxicologic Pathology, 53(1), 21-30. https://doi.org/10.1177/01926233241311275

Vancouver

Win R, Minto W, Mah IK, Boyd K. Integration of Chromogenic RNAscope In Situ Hybridization for Target Validation in Drug Discovery. Toxicologic Pathology. 2025;53(1):21-30. doi:10.1177/01926233241311275

BibTeX
@article{Win2025,
  author = {Win, Rosanna and Minto, Wesley and Mah, In Kyoung and Boyd, Kelli},
  title = {Integration of Chromogenic RNAscope In Situ Hybridization for Target Validation in Drug Discovery},
  journal = {Toxicologic Pathology},
  year = {2025},
  volume = {53},
  number = {1},
  pages = {21--30},
  doi = {10.1177/01926233241311275}
}
Kostenlos starten →